{
  "paper_id": "PMC12239805",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239805/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Process of Oncolytic virotherapy for neuroblastoma.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/a09a3bd9401b/KHVI_A_2526964_F0001_OC.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/a09a3bd9401b/KHVI_A_2526964_F0001_OC.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/a09a3bd9401b/KHVI_A_2526964_F0001_OC.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/a09a3bd9401b/KHVI_A_2526964_F0001_OC.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f0001",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/a09a3bd9401b/KHVI_A_2526964_F0001_OC.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC12239805/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/a09a3bd9401b/KHVI_A_2526964_F0001_OC.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "New development in nanocarrier drug delivery technology that crosses the bloodâ€“brain barrier.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/205559a55686/KHVI_A_2526964_F0002_OC.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/205559a55686/KHVI_A_2526964_F0002_OC.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/205559a55686/KHVI_A_2526964_F0002_OC.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/205559a55686/KHVI_A_2526964_F0002_OC.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f0002",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/205559a55686/KHVI_A_2526964_F0002_OC.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC12239805/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df62/12239805/205559a55686/KHVI_A_2526964_F0002_OC.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Neuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 30,
    "images_downloaded": 2,
    "tables_filtered": 17
  }
}